Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CGEN vs CERS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CGEN Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 8–2 Matrix Metrics)

CGEN Overall Winner 6-Pillar Tally: CGEN 3 – 3 CERS Matrix Metrics: CGEN 8 – 2 CERS

As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Cerus Corp (CERS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CGEN carries a Unified Composite Score of 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin), whereas CERS carries 54.4/100 (HOLD) at $1.90 (126.7x Forward P/E, -1.1% operating margin).

  • Composite vs. Pillar Nuance: While CERS currently prints a higher short-term Unified Composite Score (54.4/100 HOLD vs. CGEN 47.1/100 HOLD), CGEN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (41.3% vs. -1.1% operating margin) and revenue trajectory (+102.1% vs. +9.5% YoY).
  • Technical & Structure Timing Caution: CGEN is currently in a Breakdown options structure phase (RSI 46.9); meanwhile CERS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CGEN vs CERS
CGEN NASDAQ Head-to-Head Winner
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap $193.2M
TTM Revenue $76M
Forward P/E 12.4x
Beta / 30D Vol 1.44β · 62% Vol
Unified Composite Score
47.1 / 100 HOLD
Tech 44.0 Fund 52.0 Flow 54.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $2.02 · SMA50: $2.18
CERS NASDAQ
Cerus Corp
Surgical & Medical Instruments & Apparatus
$1.90
+2.15% 1D
Market Cap $375.6M
TTM Revenue $227M
Forward P/E 126.7x
Beta / 30D Vol 1.62β · 78% Vol
Unified Composite Score
54.4 / 100 HOLD
Tech 65.0 Fund 60.0 Flow 56.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.1%), weak momentum, RSI 38
RSI-14: 37.5 · SMA20: $2.20 · SMA50: $2.33

6-Pillar Scorecard Institutional Category Breakdown (CGEN 3 – 3 CERS)

Columns: Metric · CGEN · CERS
1. Valuation Multiples CGEN
Forward P/E 12.4x 126.7x
Trailing P/E 5.2x N/M
PEG Ratio 1.29x N/M
EV / Revenue 2.5x 1.9x
2. Growth & Scale CERS
Revenue Growth (YoY) +102.1% +9.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $76M $227M
Market Cap $193.2M $375.6M
3. Profitability & Quality CGEN
Gross Margin 86.2% 51.8%
Operating Margin 41.3% -1.1%
Net Profit Margin 47.9% -3.2%
Return on Equity (ROE) 57.2% -10.7%
4. Balance Sheet & Cash Flow CGEN
Cash Generation (TTM) $32M EBITDA $494,000
Cash Flow Margin 41.9% EBITDA Mgn 0.2%
Net Cash / Leverage $4.3M Net Cash $59M Net Debt (0.99x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CERS
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 89.7% (57th %ile) 44.4% (20th %ile)
Put/Call OI Skew N/A 0.66x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat CERS
OpEx & R&D Intensity 44.9% of Rev ($34M) 52.9% of Rev ($120M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CGEN (8) vs CERS (2)
Institutional Metric CGEN CERS Criterion Row Edge
Market Capitalization
Scale
$193.2M $375.6M Larger Scale CERS
Trailing P/E Ratio
Valuation
5.2x N/M Lower Multiple CGEN
Forward P/E Ratio
Valuation
12.4x 126.7x Lower Multiple CGEN
Revenue Growth (YoY)
Growth
+102.1% +9.5% Higher Growth CGEN
Operating Margin (TTM)
Profitability
41.3% -1.1% Higher Margin CGEN
Net Profit Margin
Profitability
47.9% -3.2% Higher Margin CGEN
Return on Equity (ROE)
Capital Efficiency
57.2% -10.7% Higher ROE CGEN
52-Week Range Position
Momentum
33% ($1–$3) 22% ($1–$3) Stronger Trend CGEN
Beta / 30D Volatility
Risk Regime
1.44β · 62% Vol 1.62β · 78% Vol Lower Realized Risk CGEN
Unified Institutional Score
Composite Signal
47.1 / 100 (HOLD) 54.4 / 100 (HOLD) Higher Composite CERS
Trailing 12M Revenue (USD)
Operating Scale
$76M $227M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
86.2% 51.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.29x PEG · 2.5x EV/Rev N/M PEG · 1.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$32M EBITDA ($4.3M Net Cash) $494,000 ($59M Net Debt (0.99x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CGEN +16.95 pp
CGEN: +2.54% · CERS: -14.41%
3M Horizon CGEN +16.12 pp
CGEN: -17.21% · CERS: -33.33%
6M Horizon CGEN +3.62 pp
CGEN: -26.01% · CERS: -29.63%
1Y Horizon CGEN +5.89 pp
CGEN: +23.17% · CERS: +17.28%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CGEN Revenue CERS Revenue CGEN Op. Margin CERS Op. Margin Margin Leader
FY2018 $20M $80M -130.5% -72.3% CERS
FY2019 N/A $90M N/A -70.6% CERS
FY2020 $0M $110M -1574.8% -51.1% CERS
FY2021 $10M $160M -584.6% -30.7% CERS
FY2022 $10M $190M -471.7% -18.1% CERS
FY2023 $30M $190M -38.8% -16.1% CERS
FY2024 $30M $200M -53.4% -7.1% CERS
FY2025 $70M $230M 43.1% -3.7% CGEN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CGEN BREAKDOWN
143d in phase · OBV NEUTRAL
Current IV 89.7%
IV Percentile 57th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CERS BREAKDOWN
119d in phase · OBV DISTRIBUTION
Current IV 44.4%
IV Percentile 20th %ile
Put/Call OI Skew 0.66x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CERS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CGEN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $193.2M market capitalization and 41.3% operating margin.
OpEx & R&D Reinvestment 44.9% of Rev ($34M)
90D Engineering Disclosures 0 Published
CERS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $375.6M market capitalization and -1.1% operating margin.
OpEx & R&D Reinvestment 52.9% of Rev ($120M)
90D Engineering Disclosures 0 Published

Investor FAQ CGEN vs CERS Key Questions & Quantitative Answers

As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Cerus Corp (CERS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CGEN carries a Unified Composite Score of 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin), whereas CERS carries 54.4/100 (HOLD) at $1.90 (126.7x Forward P/E, -1.1% operating margin). Composite vs. Pillar Nuance: While CERS currently prints a higher short-term Unified Composite Score (54.4/100 HOLD vs. CGEN 47.1/100 HOLD), CGEN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (41.3% vs. -1.1% operating margin) and revenue trajectory (+102.1% vs. +9.5% YoY). Technical & Structure Timing Caution: CGEN is currently in a Breakdown options structure phase (RSI 46.9); meanwhile CERS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CERS leads the Growth & Scale pillar: CGEN posts +102.1% YoY revenue growth and +0.0% YoY earnings growth on $76M TTM revenue (86.2% gross margin, 41.3% operating margin), compared with CERS at +9.5% YoY revenue growth and +0.0% YoY earnings growth on $227M TTM revenue (51.8% gross margin, -1.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CGEN cumulative revenue shifted +250.0% while CERS shifted +187.5%. In operating R&D and SG&A reinvestment, CGEN deploys 44.9% of Rev ($34M) (0 90-day corporate R&D disclosures) versus 52.9% of Rev ($120M) (0 disclosures) for CERS.

CGEN screens cheaper on headline valuation multiples. CGEN trades at 12.4x Forward P/E, 5.2x Trailing P/E, 1.29x PEG, and 2.5x EV/Revenue (41.9% EBITDA margin), whereas CERS trades at 126.7x Forward P/E, N/M Trailing P/E, N/M PEG, and 1.9x EV/Revenue (0.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CGEN (57.2% ROE) versus CERS (-10.7% ROE) capital efficiency.

In options market volatility and institutional positioning, CGEN carries 89.7% implied volatility (57th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 62% Vol realized risk). By comparison, CERS carries 44.4% implied volatility (20th %ile, Compressed (<25th %ile)), a 0.66x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.62β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.